The CHECKMATE-7FL trial evaluates the efficacy of nivolumab, an anti-PD-1 antibody, in combination with neoadjuvant endocrine therapy for HR-positive, HER2-negative early breast cancer. This evidence concerns the gene ERBB2 and breast cancer.